论文部分内容阅读
目的 :研究新生儿支气管肺发育不良(bronchopulmonary dysplasia,BPD)血清可溶性晚期糖基化终末产物受体(soluble Receptor for advanced glycation end products,sRAGE)检测的意义。方法:选取新生儿重症监护病房住院BPD患儿45例(轻、中、重组分别为10、16、19例),在病程的不同时期以ELISA法检测血清中sRAGE水平,同时选取匹配非BPD患儿作为对照组。结果:与对照组相比,BPD组血清sRAGE水平明显增高;BPD组中,sRAGE在轻、中、重组间差异也有显著性(F=149.97,P<0.01)。结论:血清sRAGE可作为BPD的诊断和病情轻重评估的敏感指标。
Objective: To investigate the significance of sRAGE in neonatal patients with bronchopulmonary dysplasia (BPD) and their serum soluble advanced glycation end products (sRAGE). Methods: Forty-five inpatients with BPD were selected from neonatal intensive care unit (10, 16, 19 cases). Serum levels of sRAGE were detected by ELISA at different stages of the course of the disease. Matching non-BPD patients Children as a control group. Results: The level of sRAGE in BPD group was significantly higher than that in control group. In the BPD group, sRAGE was also significantly different between mild, moderate and severe groups (F = 149.97, P <0.01). Conclusion: Serum sRAGE can be used as a sensitive indicator for the diagnosis and assessment of severity of BPD.